Treatment of advanced, progressive epidemic Kaposi's sarcoma (EKS): a phase-II study

Onkologie. 1988 Feb;11(1):61-2. doi: 10.1159/000216486.

Abstract

The design of a prospective phase-II study on the treatment of Kaposi's sarcoma (KS) in patients with HIV infection is described. In this study the toxicity and antineoplastic activity of high-dose alpha-interferon (20 x 10(6) U/m2 s.c. daily) will be investigated in patients with advanced and progressive KS. Patients with progressing KS during IFN treatment or with relapsing KS after IFN will be treated with vinblastine (4 mg/m2 i.v., days 1, 8, and 15) and bleomycin (15 mg i.v., days 1 + 8). The study was only recently activated; results are so far not available.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / therapy*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Combined Modality Therapy
  • Drug Evaluation
  • Humans
  • Interferon Type I / therapeutic use*
  • Recombinant Proteins / therapeutic use*
  • Sarcoma, Kaposi / drug therapy
  • Sarcoma, Kaposi / therapy*
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / therapy*
  • Vinblastine / administration & dosage

Substances

  • Interferon Type I
  • Recombinant Proteins
  • Bleomycin
  • Vinblastine